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Summary This systematic review assessed the potential benefits of growth factors for bone
augmentation prior to the placement of dental implants in human.
A systematic online review of the Medline database, using the PubMed search machine was
performed between 1966 and November 2008 by entering the MeSH terms. The primary outcome
of the included studies was bone regeneration of localized alveolar ridge defects.
The initial search identified119papers fromtheelectronicdatabase. This reviewproducedseven
eligible papers that reported on bone augmentation with recombinant human Bone Morphogenetic
Protein-2 (rhBMP-2), recombinanthumanPlatelet-DerivedGrowth Factor (rhPDGF) andPlasma-Rich
Growth Factor (PRGF). The rhBMP-2 affected local bone augmentation with increasing volume for
higher doses. Both rhPDGF and PRGF showed a positive effect in favor of the growth factor.
Differing levels and quantity of evidence were noted to be available for the growth factors
evaluated, revealing that rhBMP-2, rhPDGF, and PRGF may stimulate local bone augmentation to
various conditions. Especially the potential of rhBMP-2 is supportive. However, the confined number
of investigators using these techniques and the low number of patient treatments reported in the
literature, the generalizability of this approach is limited at this time.
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Dental implants are the most innovative and superior treat-
ment in dentistry, and are widely used for a variety of cases.
Most of the techniques that are used are evidence-based and
predictable. However, in many cases, the intended implant
site is inappropriate due to the poor bone quality or to an
insufficient quantity of bone. An insufficient alveolar ridge
height is often related to the proximity of the implant site to
other anatomical structures, i.e., the maxillary sinus or the
mandibular canal.
In order to overcome some of these difficulties, autoge-
nous bone grafts taken from the chin, the ramus of the
mandible, or the iliac crest of the same patient have histori-
cally been the standard for alveolar reconstruction, specifi-
cally, due to their osteoconductive, osteoinductive, and lack
of immunogenic properties. However, the adverse events and
complications, such as infection, pain, sensory loss, and
hematoma formation at the donor site, occur frequently
upon autogenous bone graft treatment. In addition, a donor
site with a sufficient quantity of bone is not always available.
Allograft bones, bones taken from a different person and
processed and managed by a tissue bank or commercial
supplier, have often been substituted. However, this method
also has limitations, including an inconsistent osteoinductive
activity, unfavorable host immune responses [1], a delayed
resorption, and a risk for prion and virus transmissions [2,3].
An ideal bone graft in implant dentistry should have the
following properties: it should be biomimetic; it should have
the ability to induce differentiation of the appropriate cells
(i.e., endothelial and osteoblastic cells) for the formation of
new bone; it should be easily synthesized or produced, rather
than extracted from allograft materials (to eliminate all risks
of disease transmission); it should be easily and quickly
resorbed as the osteogenic response occurs; it should have
no immune-provoking properties; it should be easily trans-
ported and stored; it should be reasonably cost-effective; it
should be capable of achieving consistent and predictable
results without being affected by different level of technical
ability of the clinician.
In order to meet these demands, dental research has
focused on the use of bioactive molecules to induce local
bone formation. Since the various growth factors that have
an effect on the bone regeneration have been discovered,
the number of related studies has increased substantially. In
particular, the factors recombinant human Bone Morphoge-
netic Protein-2 (rhBMP-2) [4—7] and recombinant human
Platelet-Derived Growth Factor (rhPDGF) [8—10] have been
shown to induce bone formation at the compromised sites in a
variety of experimental and clinical situations. These factorshave also been approved by the U.S. Food and Drug Admin-
istration (FDA) for use in dentistry.
To date, there is only limited evidence to support the
application of growth factors for local bone augmentation in
dentistry. The aim of this systematic review was to summar-
ize the current literature that describes the use of growth
factors in conjunction with dental implants.
Material and methods
Study selection
We conducted an electronic search of the Medline database,
using the PubMed search machine, for the relevant selection
of studies by entering the following MeSH terms: ‘‘Intercel-
lular Signaling Peptides and Proteins;’’ and ‘‘Dental
Implants’’. We limited our results to humans, to articles
published in the English language; and, in the time range
of 1966 to November 2008. The references of the retrieved
articles were also searched.
The inclusion and exclusion criteria
The studies included in this review met the following inclu-
sion criteria: (1) only relevant data on bone augmentation
induced by the growth factors; (2) only randomized, non-
randomized clinical trials, cohort studies, case—control stu-
dies, and case reports; (3) only studies with a clearly written
amount and concentration of growth factors or using the kit
with fixed concentration of growth factors; (4) only studies
with a clearly defined baseline; and (5) only studies with the
application of titanium root-form implants. The most recent
report was used if more than one publication referred to the
same data. The studies that did not meet all the inclusion
criteria were excluded from the review. The studies that
dealt with the following topics were excluded: (1) in vitro
animal studies; (2) studies using gene therapy; (3) studies
with a focus on periodontal regeneration; (4) studies report-
ing systemic treatment outcomes; (5) craniofacial surgery for
total or partial reconstruction of mandibles/maxillas; (6)
cleft lip and palate surgeries; (7) distraction osteogenesis;
(8) osseointegration; (9) implant anchor; (10) immediate
loading or (11) orthopedic surgeries. Each retrieved citation
was reviewed by two independent reviewers (K.S., O.M.).
Most of the citations were excluded immediately, due to the
information provided by the title or the abstract. If the
citation could not be excluded immediately because of its
equivocal nature, then the complete article was selected by
the two reviewers. Any disagreement between the reviews
was resolved by a consensus. To avoid any bias, the search
Figure 1 Outline of the literature search.
Growth factors for bone augmentation 45process was blinded to the names of the authors, to the
names of institutions, and to the names of the journals.
The data extraction
The data were independently extracted by two reviewers
using data extraction tables. Any disagreements were dis-
cussed until they were resolved by a consensus. The following
information were extracted: the authors, the year of pub-
lication, the study design, the number of patients, the mean
age of the patients, the follow-up period, the adverse event,
the applied dose of growth factor, the carrier system, the
control group, the type and the dimension of the defect, the
decrease in the defect of height/increased bone height/
width, the newly formed bone, and the new bone density.
Result
The study characteristics
The PubMed search identified a total of 119 citations. How-
ever, most of them were excluded immediately due to the
information provided by the title or the abstract (Fig. 1). Only
20 articles were selected for further text review [11—30].
The main reasons for excluding some studies (n = 13), after
the full text was obtained, were as follows: poor-quality data
for bone augmentation induced by growth factors, any
reports based on animal studies, and a lack of or insufficient
discussion of the clinical, radiographic, or histological treat-
ment outcomes (only descriptive presentation of results). Of
the seven eligible articles, three studies reported on bone
augmentation with rhBMP-2 [14,15,17], three studies dis-
cussed the effect of rhPDGF [11—13], and one study exam-
ined the effect of Plasma-Rich Growth Factor (PRGF) [16].
Two of the rhBMP-2 studies were randomized control trials
(RCT) with a clearly stated random allocation of subjects.
The other BMP-2 study was a prospective, human clinical trial
without a control. All of three rhPDGF studies and the PRGF
study were case reports.
Table 1 shows the characteristics of the included studies.
A total of 76 patients were treated with growth factors for
local intra-oral bone regeneration. The mean age of the
patients was 54.8 years and the mean follow-up period
was 47.1 months. Table 2 shows the operative data reported
in the included studies. The growth factors were always
administered locally, and the root form dental implant was
used in every study. The applied dose of the rhBMP-2 ranged
from 0.43 to 1.5 mg/ml or from 0.2 to 24 mg/patient. How-
ever, the rhPDGF and the PRP studies lacked this type of
information. Two different carrier systems were used for the
application of rhBMP-2. An absorbable collagen sponge (ACS)
was used in two studies [14,17], whereas rhBMP-2 was
applied to a demineralized bovine bone matrix (xenogenic
bone substitute mineral, Bio-Oss1) in another study [15].
With respect to the application of rhPDGF, the carriers used
were Bio-Oss1, beta-tricalcium phosphate (b-TCP) and a
freeze-dried mineralized bone allograft (FDBA). For the PRGF
treatment, a combination of Bio-Oss1 and autogenous bone
was used. The types of local bone augmentations observed
were sinus floor augmentations [14,16,17], preservations of
extraction socket [13,17], alveolar ridge bone augmentation
[11], and lateral ridge augmentation in combination withsimultaneous implant placement [12,15,16]. A meta-analysis
of the outcomes was not performed because of the hetero-
geneity of the studies (various indications, RCT, or cohort)
Bone height increase/defect size decrease
An increase in bone height, ranging from 10.16  4.7 to
9.47  5.72 mm for the sinus lift procedures, and a change
in bone depth of 6.8  0.2 mm, for the extraction socket
augmentations, were reported for the sites treated with
rhBMP-2 (Table 3). Two RCTs included control groups without
the application of the rhBMP-2 [14,15]. In comparison to the
controls, the effect of rhBMP-2 showed substantial variabil-
ity. Boyne et al. presented negative data for the bone height,
and the average gain in the bone height was 11.29  4.12 mm
for the control sites and 9.47  5.72 mm for test sites with a
low dose of rhBMP-2, respectively. There were no statistically
significant differences in the control group with respect to
the increase in ridge height, and the decrease in ridge width
with the use of rhBMP-2 [14]. Only one RCT reported a
positive effect in comparison to the control group, when
the factor was applied to the lateral ridge augmentation [15].
On the other hand, rhPDGF seemed to have a positive role
in enhancing the healing of soft and hard tissues, even though
there was no clear mention and evaluation of bone regen-
eration. The result of the bone augmentation was clearly
presented by the use of pictures and dental X-rays that
showed successfully filled bone defects within 5—7 months
after the operation [11—13].
New bone formation
Jung et al. and Boyne et al. reported the new bone formation
as a percentage of the original defect or as new bone density,
respectively (Table 3). The dose of the applied factor seemed
to have an impact on the treatment outcome, with a higher
local bone regeneration for the higher doses of rhBMP-2. For a
lower dose of rhBMP-2, a positive, but not a statistically
significant effect was observed on the bone formation,
whereas, for a higher dose, a positive and statistically sig-
nificant effect was reported. Boyne et al. reported a sig-
nificant difference in new bone density in favor of the bone
Table 1 Characteristics of included studies.
Study Year of
publication
Type of
study
Type of surgical
procedure
No. of enrolled patient Mean
follow-up
(month)
Mean age M/F ratio Outcome
Treatment group Control
group
Total Treatment
group
Control
group
Treatment
group
Control
group
Simion et al. 2008 Case report Alveolar ridge
augmentation
1 0 1 14 36 years — 0 — X-ray
Byun et al. 2008 Case report Socket
preservation
1 0 1 ND 65 years — 0 — X-ray
Fagan et al. 2008 Case report Socket
preservation
1 0 1 3 52 years — 1 — X-ray, histology
Boyne et al. 2005 RCT Sinus floor
augmentation
Low dose: 18;
high dose: 17
13 48 52 Low dose:
57 years  12;
high dose:
52 years  7
57 years
 11
Low dose:
0.80; high
dose: 0.54
0.625 CT, histology,
success and
survival rate
Jung et al. 2003 RCT Alveolar ridge
augmentation
11 — 11 ND 53 years  16.9 — 0.57 — Defect filling rate,
histology
Anitua 2001 Case report Alveolar ridge
augmentation
Sinus floor
elevation
2 0 2 36 61 years  4.2 — 1 — Histology
Cochran et al. 2000 Prospective
clinical trial
Alveolar ridge
augmentation
Socket
preservation
12 0 12 36 ND — ND — Defect filling rate,
histology
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Table 2 Operative data investigated in the included studies.
Study Treatment group Control group Implant system Number of
implant
Type of growth factor Dose of growth factor Delivery vehicle Concentration of
growth factor
Type of bone
graft
Simion et al. rhPDGF-BB (GEM21S1;
BioMimetic)
ND Bio-Oss1 +
autogenous bone
1.2 mg/ml — MK3 Natural Platform
3.3 mm  15 mm,
Speedy Groovy 4 mm
 15 mm, Nobel biocare
2
Byun et al. rhPDGF-BB (GEM21S1;
BioMimetic)
ND b-TCPalloplast,
autogenous bone
0.3 mg/ml — Tapered ScrewVent
3.7 mm  ND mm,
Zimmer Dental
1
Fagan et al. rhPDGF-BB (GEM21S1;
BioMimetic)
ND FDBA 0.3 mg/ml — Osseotite implant
4 mm  13 mm,
BIOMET/3i
1
Boyne et al. rhBMP-2 (Medtronic) Low dose: 8.9 mg
(5.2—12.0 mg);
high dose: 20.8 mg
(10.8—24.0 mg)
Autogenous bone
or ACS
Low dose:
0.75 mg/ml;
high dose:
1.5 mg/ml
Autogenous
bone graft
ND 219
Jung et al. rhBMP-2 0.18 mg Bio-Oss1 0.5 mg/ml Bio-Oss1 Machine surface,
Nobel biocare
34
Anitua PRGF (PRP) ND Bio-Oss1 +
autogenous bone
ND — ND 5
Cochran et al. rhBMP-2 Alveolar ridge
augmentation
0.27 mg (0.1—0.9 mg),
Socket preservation
0.83 mg (0.2—1.7 mg)
ACS 0.43 mg/ml — Titanium plasma
sprayed implant
13
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Table 3 Summary of the clinical bone assessment.
Study Group Defect fill Histological analysis CT analysis
Base line
(mm)
Change from
base line
(mm)
Percent
vertical
defect fill (%)
Woven
bone (%)
Lamellar
bone (%)
Bone
substitute
mineral (%)
Bone density
at 4 months
(mg/cm3)
Bone density 6 months
post-functional
loading (mg/cm3)
Simion et al.
Control — — — — — — — —
Test rhPDGF-BB/Bio-Oss1
+ autogenous bone
Depth 20 ND ND ND ND ND
Width 15 ND ND
Byun et al.
Control — — — — — — — —
Test rhPDGF-BB/P-TCP
+ autogenous bone
Depth ND ND ND ND ND ND
Width ND ND ND
Fagan et al.
Control — — — — — — — —
Test rhPDGF-BB/FDBA Depth 15 ND ND 48 19 14
Width 8 ND ND
Boyne et al.
Control Autogenous bone graft Height 11.29  4.12 ND ND 350  243 448 + 213
Width at 1/4 4.66  2.75 ND ND
Width at 1/2 10.17  2.98 ND ND
Width at 3/4 10.56  3.17 ND ND
rhBMP-2/ACS 0.75 mg/ml Height 9.47  5.72 ND ND 84  50 456  131
Width at 1/4 2.02  2.73 ND ND
Width at 1/2 8.54  5.47 ND ND
Width at 3/4 11.86  5.15 ND ND
Test rhBMP-2/ACS 1.50 mg/ml Height 10.16  4.7 ND ND 137  77 508  126
Width at 1/4 1.98  2.41 ND ND
Width at 1/2 7.8  3.87 ND ND
Width at 3/4 10.78  4.63 ND ND
Jung et al.
Control Bio-Oss1 Depth 5.8  1.8 5.4  2.2 91  15.1 13  6.7 17  8.1 17  11.0
Width ND ND ND
Test rhBMP-2/Bio-Oss1 Depth 7.0  2.7 6.8  0.2 96  6.9 8  5.0 29  11.3 23  11.1
Width ND ND ND
Anitua
Control — — — — —
Test PRGF (PRP) Depth 10 ND ND
Width ND ND ND
Cochran et al.
Control — — — — —
Test Alveolar ridge
augmentation
Height ND 0.8  2.5 ND
Width ND 0.4  0.9 ND
Socket preservation Depth ND 10.4  6.6 ND
Width ND 4.9  2.4 ND
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Growth factors for bone augmentation 49graft group (350  243 mg/cm3) in comparison to the low
(84  50 mg/cm3) and to the high (137  77 mg/cm3) dose
treatment groups at 4 months after the operation. However,
after 6 months of functional loading, the density of the newly
induced bone increased significantly for the low
(456  131 mg/cm3) and the high (508  126 mg/cm3) dose
treatment groups, and its value was comparable to that of
the bone graft group (448  213 mg/cm3). Jung et al.
reported a positive, but not statistically significant, effect
of rhBMP-2 on the amount of newly formed bone (37  11.2%)
in comparison to the control group (30  8.9%). However, a
statistically significant increase in mature lamellar bone
(29  11.3%) for the test site was found in comparison to
the control site (17  8.1%).
Safety
From the various studies, Boyne et al. [14] and Cochran et al.
[17] reported the adverse events of the rhBMP-2 application
that occurred during the procedure (Table 4). The most
frequent adverse events occurred during the first 4 months
after the operation. These events were transient and con-
sistent with the surgical procedures performed (a maxillary
sinus floor augmentation procedure, or a bone graft harvest
procedure). The majority of the events were equally dis-
tributed among the treatment groups. However, the inci-
dence of edema, rash and pain in the bone graft group were
much higher than in the rhBMP-2 groups. These complaints of
edema, rash (erythema), and pain were experienced from
the autograft harvest site. Notably, the 1.50 mg/ml rhBMP-2/
ACS treatment group had significantly greater facial edema
during the first 4 months after surgery than did the bone graft
group and the 0.75 mg/ml rhBMP-2/ACS group.
Discussion
This systematic review assessed the potential benefits of
growth factors for bone augmentation prior to the placement
of dental implants. The rhBMP-2 (INFUSE1, Medtronic) and
the rhPDGF (GEM21S1, BioMinetic Therapeutics) have been
approved by the FDA for dentistry. In addition, the rhBMP-7
(OP-1, Stryker Biotech) has been approved in Australia and
Europe, and by the orthopedic community in the USA. Various
growth factors are now entering clinical practice in dentistry.
Hence, a systematic assessment of the effect of the growth
factors on the bone augmentation for dental implants is very
important.
The number of satisfactory studies was assumed to be low;
therefore, in this systematic review with the prospective
cohort studies and case reports, a lower level of evidence was
used. Instead of performing a formal quality assessment of
the included studies and a sensitivity analysis, this review
used stringent inclusion criteria. The electronic search
selected the studies, that used growth factors for bone
augmentation prior to the placement of dental implants in
human, by applying the following MeSH terms: ‘‘Dental
Implant’’ and ‘‘Intercellular Signaling Peptides and Pro-
teins’’. The term, ‘‘Intercellular Signaling Peptides and Pro-
teins’’, belongs to the chemical and drug category, and is
located at the upper level of the MeSH tree that contained all
the growth factors. However, only seven studies of the
50 K. Shimono et al.rhBMP-2, the rhPDGF, and the PRGF were available for an
analysis. Two human RCTs for rhBMP-2 were found, but for
rhPDGF and PRGF no human RCT was found. Almost all the
articles were old, and no RCTevaluation of the effect of the
growth factors for the dental implants had been published
recently. Seven eligible articles demonstrated that the appli-
cation of growth factors was safe and effective for bone
formation.
Three articles related to rhBMP-2, includes this systematic
review, showed a positive effect on the rhBMP application for
bone formation. Cochran et al. reported a prospective,
human clinical trial without a control in order to examine
the effect and safety of rhBMP-2/ACS on the alveolar ridge
augmentation and on the socket preservation. This study
showed that bone formation was successful when using
rhBMP-2/ACS at a concentration of 0.43 mg/ml. Jung et al.
reported a prospective, controlled, randomized, double-
masked clinical study on alveolar ridge augmentation. This
studywas designed to investigate the test site and the control
site of the same patient’s jaw, which required a lateral ridge
augmentation. Despite the small number of patients, this
experimental design allows the direct comparison of the test
site and the control site by eliminating the differences such
as the patients and the doctors or other possible variables. In
addition, this is the only report that tested rhBMP-2 with
grafting material (xenogenic bone substitute; Bio-Oss1) for
lateral bone augmentation. The report concluded that the
combination of Bio-Oss1 with the rhBMP-2 was able to
enhance the maturation process of bone regeneration and
increase the graft-to-bone contact in humans. The most
recent RCT study was reported by Boyne et al., and it was
designed to evaluate the effect of two different concentra-
tions of BMP-2 on the safety and efficacy of the sinus floor
augmentation. It was demonstrated that the higher dosage
produced better results. Based on the data, they concluded
the following: (1) both the high (1.50 mg/ml) and the low
(0.75 mg/ml) concentrations of rhBMP-2 were safe, with a
safety profile similar to that of bone graft; (2) both concen-
trations of rhBMP-2 induced a similar amount of bone for-
mation which was similar to that induced by the bone graft;
and (3) the higher concentration of rhBMP-2 induced bone
formation more rapidly in comparison to the lower concen-
tration. The results support the use of rhBMP-2/ACS at a
concentration of 1.50 mg/ml for the future studies of max-
illary sinus floor augmentation. In these studies, the most
frequent adverse events occurred within the first 4 post-
operative months [14,17]. The majority of the events were
equally distributed among the treatment groups and control
groups. However, the high (1.50 mg/ml) concentration of
rhBMP-2 treatment group had a significantly greater facial
edema during the first 4 months after surgery in comparison
to the bone graft group and the 0.75 mg/ml rhBMP-2/ACS
group. On the other hand, we could not obtain a clear
outcome from the three case reports that evaluated the
rhPDGF efficacy and that met our inclusion criteria. However,
the results of every study were consistent with respect to the
positive effect of rhPDGF. In addition, there is no well-
designed RCT study of rhPDGF. Therefore, the information
was not sufficient to draw any definitive conclusions, parti-
cularly with respect to the long-term evaluation.
In addition to this systematic review, we also obtained
another six eligible articles [31—36] by means of a hand-search of the articles listed in the retrieved list of Refer-
ences. These studies assessed — only the bone grafts. They
were most likely automatically excluded on the PubMed
during our selection process because the word ‘‘Dental
Implant’’ was not associated strongly with these articles.
The first studies were clinical trials, one of which was a
multicenter cohort study of the effect of rhBMP-2 maxillary
sinus floor augmentation and socket preservation [31,32]
that supports the beneficial effect of BMPs. Fiorellini
reported a randomized, masked, placebo-controlled multi-
center clinical study to evaluate the effect of two concen-
trations of rhBMP-2 on the safety and efficacy of socket
preservation [33]. The trend of this study was the same as
that of the Boyne’s study; 1.5 mg/ml of rhBMP-2 was safe for
clinical application and the higher dosage produced better
results. Van den Bergh et al. [34] and Groeneveld et al. [35]
have used rhBMP-7 as an aid to increase the bone height in
sinus, prior to the placement of implants. The results from
these clinical trials indicated that the OP-1 (2.5 mg in 1 g of
collagen carrier) had the potential to initiate bone formation
in the human maxillary sinus within 6 months after a sinus
floor elevation operation. However, the behavior of this
material cannot be fully predicted.
Dickinson et al. [36] reported about the economic result of
the rhBMP-2 treatment on the alveolar bone grafting in the
older cleft patients, in order to improve poor wound healing,
graft exposure, recurrent fistula, and failure of tooth erup-
tion. According to the report for the autogenous bone graft
group, seven of the nine patients underwent the procedure
on an outpatient basis. The procedure was applied to the iliac
bone graft patients on an inpatient basis. The donor-site pain
intensity and the frequency were significant in the traditional
iliac bone graft, but it was not significant in the rhBMP-2
treated group. Furthermore, the mean length of stay was
greater for the iliac bone graft patients at 1.8  0.8 days in
comparison to the patients treated with rhBMP-2 at 0.4  0.4
days ( p < 0.05). Hence, the mean overall cost of the proce-
dure, including the surgeon, the facility, the equipment, and
the anesthesia fees, was greater for the iliac bone graft group
($21,800) in comparison to the rhBMP-2 treated group
($11,100).
On the other hand, the price of those growth factors is still
relatively costly for treatment. The price of INFUSE1 kit
which contains 4.9 mg of rhBMP-2 cost more than $3000 in the
United States. The rhBMP-2 and the rhBMP-7 have been used
in orthopedic spinal surgery with decreased donor-site mor-
bidity. In addition, these proteins showed promise for the
tissues that are characterized by poor wound healing, such as
irradiated tissue [37]. However, there are several reports on
the side effects associated with the high BMPs dosage and the
repeated regimens, which are required for the stable bone
regeneration in the orthopedic field [38—40]. As shown here,
the use of growth factors in humans undergoing craniofacial
and oral maxillofacial procedures has only recently been
documented. There have been investigative reports of ecto-
pic bone growth with rhBMP-2 and, consequently, its use in
growing patients is being studied carefully [41]. In order to
overcome some of these difficulties, a variety of pre-clinical
studies are carried out; such as testing new optimized carrier
systems to decrease the dosage of growth factors, producing
the growth factors by using E-coli system [42,43], or finding
the new bioactive small peptide which have osseoinduction
Growth factors for bone augmentation 51ability [44] to reduce the production costs and developing a
genetically engineered mutant growth factors to improve the
binding property to the extracellular matrix in order to
prevent rapid diffusion.
BMPs have been shown to increase the formation of bone
nodules in vitro [45—56] and stimulate bone formation in
vivo. But the dosage applied in these clinical studies was
several orders of magnitude higher than the concentration of
naturally occurring BMPs [57]. It is believed that small ani-
mals require a much lower dose of BMPs to bridge bone
defects in comparison to larger animals, although this cor-
relation is expected to change appropriately for specific
carriers [58]. Hydroxyapatite, natural bone mineral, col-
lagen, gelatin hydrogels and other biodegradable polymers
compose the range of carriers that are currently being
investigated as vehicles for the implantation of osteogenic
factors. More recently, the attention of researchers in the
biomaterial field was directed at the relationship between
tissue engineering and bone morphogenesis. The fundamen-
tal principle governing these investigations is the production
of more ‘‘intelligent’’ materials that could influence protein
pharmacokinetics to modulate the delivery of rhBMP-2 at the
site of implantation, or to enhance osteogenesis with these
factors by altering the geometry of the environment [59—62].
Recently several groups have developed genetically mod-
ified mutant rhBMP-2, which is generated from E-coli, and
this rhBMP-2 possesses an improved binding property to the
extracellular matrix in order to prevent its rapid diffusion
[42,43]. Wurzler et al. reported a genetically engineered
mutant rhBMP-2 (rhBMP-2 T4), which was developedwith two
additional repeats of a positively charged epitope, called the
heparin-binding domain, in the N-terminal sequence. Bing
et al. reported a genetically engineered collagen targeting
rhBMP-2 (rhBMP-2-v), which was fused with collagen bonding
peptide to the N-terminal of rhBMP-2. Their rhBMP-2-v con-
tained a collagen-binding domain which modified from von
Willebrand factor, and this collagen-binding domain was
flanked by linker regions to minimize steric hindrance. Both
genetically engineered mutant rhBMP-2 have been shown to
have higher extracellular matrix binding and stronger
osteoinductivity than the wild-type rhBMP-2 in vitro and in
vivo. By concentrating at the targeted wound site, these
BMP-2 mutants can be avoids being washed away by extra-
cellular fluids, which will eventually lead to not only a more
effective osteogenesis but also a reduction of the undesirable
systemic side effects.
Therefore, many questions must be answered before the
growth factors can attain widespread clinical usage. Knowl-
edge of the cellular and molecular basis of the bone regen-
erative signaling pathways, and the development of
appropriate carriers will certainly stimulate a great revolu-
tion in dentistry, thus allowing the dominance of regenera-
tive over cicatricial processes. However, the number of well-
designed blind and randomized clinical trials is still too small
to establish the clinical protocols for the improvement of a
recipient bone bed prior to implant placement, or to
enhance the integration process of an implant. The dissim-
ilarities in the experimental designs, as well as, the use of
nonstandardized concentration of growth factors, or the
type of carriers of growth factors by different authors make
it difficult to compare the outcomes of the growth factor
applications in implant dentistry. A better-designed RCT,using growth factors for intra-oral bone augmentation,
especially longitudinal clinical studies with a wider patient
population, is necessary. However, these studies in this
paper will set a golden standard for examining the effect
of following new therapeutics.
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